TABLE 5.

Evaluation for synergy of combinations consisting of TOB-CIP and mitomycin C against MDR clinical isolates of Enterobacteriaceae.

Organism	MICMitomycin C [MICcombo], μg/mL	MICTOB–CIP [MICcombo], μg/mL	FIC index	Interpretation	Absolute MICMitomycin C,a μg/mL	Fold potentiationb
E. coli 94393	1 [0.125]	>128 [1]	0.125 < × < 0.133	Synergy	0.125	8-fold
E. coli 94474	2 [0.25]	>128 [4]	0.125 < × < 0.156	Synergy	0.25	8-fold
E. coli 107115	1 [0.031]	>128 [2]	0.031 < × < 0.047	Synergy	0.031	32-fold
K. pneumoniae 113250	1 [0.25]	>128 [16]	0.125 < × < 0.375	Synergy	0.5	2-fold
K. pneumoniae 113254	2 [0.25]	>128 [16]	0.125 < × < 0.250	Synergy	0.5	4-fold
K. pneumoniae 116381	8 [0.5]	>128 [1]	0.062 < × < 0.070	Synergy	0.25	32-fold
E. cloacae 117029	4 [0.5]	>128 [2]	0.125 < × < 0.156	Synergy	1	4-fold
E. cloacae 118564	8 [1]	>128 [1]	0.125 < × < 0.133	Synergy	1	8-fold
E. cloacae 121187	0.062 [0.031]	>128 [0.5]	0.500 < × < 0.504	Additive	0.031	2-fold

^aMIC of mitomycin C in the presence of 4 μg/mL TOB-CIP. ^bFold potentiation of mitomycin C in the presence of 4 μg/mL TOB-CIP.